Stocks · News reference
Wedbush has revised its price target for Perspective Therapeutics to $9 from $11 while maintaining an Outperform rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Perspective Therapeutics reported positive incremental data from its Phase 1/2a trial of [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, with plans for an end-of-Phase 2 meeting in early 2027.
Filed: 2026-11-06 AccNo: 0001193125-26-450709 Size: 17 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
RBC has downgraded Perspective Therapeutics to Sector Perform from Outperform and reduced its price target to $4 from $14.
Perspective Therapeutics released clinical trial data for its radiopharmaceutical program and held a conference call on October 23, 2026, to discuss results presented at the ESMO Congress 2026.
SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in